What should be maintained in patients after administration of alteplase during resuscitation?

In the context of administering alteplase, which is a tissue plasminogen activator used for the management of certain types of ischemic strokes and myocardial infarctions, continuous cardiac monitoring is essential. This is due to the risk of potential complications such as arrhythmias or hypotension following thrombolytic therapy. Continuous monitoring allows healthcare providers to identify and address any cardiac events promptly.

Maintaining anticoagulation after the administration of alteplase is a significant consideration. However, the standard practice involves careful management of antithrombotic therapy post-thrombolysis to minimize the risk of bleeding, rather than full anticoagulation, as the combination may increase the risk of hemorrhagic complications. This highlights the importance of individualized patient management and the use of adjunct therapies as appropriate.

Fluid resuscitation is generally important in various clinical contexts but is not specifically required as a maintenance strategy following alteplase administration unless the patient is showing signs of dehydration or hypovolemia.

High-dose vitamin supplements are not standard care post-alteplase administration and do not have a role in resuscitation or recovery in this context.

Thus, the correct focus should be on maintaining continuous cardiac monitoring to ensure patient safety during the management process with altepl